SSY Group (HKG:2005) said its 5-milliliter Composite Potassium Hydrogen Phosphate Injection and 5-milligram Vortioxetine Hydrobromide Tablets have obtained the National Medical Products Administration of China's approval for drug production and registration, a Monday Hong Kong bourse filing said.
The said injection is a compound used for the correction of hypophosphatemia in adult and child patients and parenteral nutrition in adult and child patients when enteral nutrition is impossible or insufficient.
The tablet is used for the treatment of depression in adults and has already obtained bulk drug approval from the authorities.
With the said approvals, the injection and the tablet, being under type 3 and type 4 chemical drugs respectively, are regarded as having passed the consistency evaluation.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。